Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neural EGFL-like protein 1 (NELL1) is a secreted osteogenic growth factor primarily expressed in skeletal tissues, with powerful effects on bone and cartilage formation, stem cell differentiation, and inhibition of inflammation. Its molecular mechanism involves binding to integrin β1, acting as a ligand for receptors such as CNTNAP4 and Robo2, and driving differentiation via key developmental signaling pathways (MAPK, Wnt/β-catenin, Hedgehog, RUNX family, Notch). It has shown therapeutic potential in preclinical animal models for bone regeneration and osteoarthritis, often in synergy with BMP-2, with the advantages of being anti-adipogenic, anti-inflammatory, and promoting vascularization. Modulation of NELL1 holds promise for treating bone loss diseases, though challenges remain regarding biological stability and potential adverse effects with overexpression.
Stimulates bone formation via activation of several pathways: MAPK signaling, Wnt/β-catenin pathway, Hedgehog signaling, RUNX2 and RUNX3 transcription factors, Integrin β1-mediated cell adhesion, Modulation of Notch pathway (with isoforms). Inhibits adipogenesis and modulates inflammation in tissue repair.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neural EGFL-like protein 1 (NELL1).